

Todd Hulgán

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3994537/publications.pdf>

Version: 2024-02-01

101
papers

3,043
citations

218677

26
h-index

175258

52
g-index

102
all docs

102
docs citations

102
times ranked

3793
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. <i>Aids</i> , 2004, 18, 2391-400.	2.2	429
2	Education of Physicians-in-Training Can Decrease the Risk for Vascular Catheter Infection. <i>Annals of Internal Medicine</i> , 2000, 132, 641.	3.9	314
3	Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 527-531.	2.1	222
4	Greater Weight Gain in Treatment-naïve Persons Starting Dolutegravir-based Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2020, 70, 1267-1274.	5.8	218
5	Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. <i>Aids</i> , 2005, 19, 1341-1349.	2.2	129
6	Oxidant Stress Is Increased during Treatment of Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2003, 37, 1711-1717.	5.8	105
7	Race and Sex Differences in Antiretroviral Therapy Use and Mortality among HIV-Infected Persons in Care. <i>Journal of Infectious Diseases</i> , 2009, 199, 991-998.	4.0	101
8	Absolute Count and Percentage of CD4+Lymphocytes Are Independent Predictors of Disease Progression in HIV-Infected Persons Initiating Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2007, 195, 425-431.	4.0	63
9	Adipose Tissue and Immune Function: A Review of Evidence Relevant to HIV Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1194-1201.	4.0	57
10	Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. <i>Aids</i> , 2006, 20, 1503-1513.	2.2	53
11	CD4 Lymphocyte Percentage Predicts Disease Progression in HIV-Infected Patients Initiating Highly Active Antiretroviral Therapy with CD4 Lymphocyte Counts >350 Lymphocytes/mm ³ . <i>Journal of Infectious Diseases</i> , 2005, 192, 950-957.	4.0	52
12	Identification of a CCR5-Expressing T Cell Subset That Is Resistant to R5-Tropic HIV Infection. <i>PLoS Pathogens</i> , 2007, 3, e58.	4.7	49
13	Hemochromatosis Gene Polymorphisms, Mitochondrial Haplogroups, and Peripheral Lipodystrophy during Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2008, 197, 858-866.	4.0	46
14	Drug Use and Receipt of Highly Active Antiretroviral Therapy among HIV-Infected Persons in Two U.S. Clinic Cohorts. <i>PLoS ONE</i> , 2011, 6, e18462.	2.5	43
15	European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142*. <i>Aids</i> , 2011, 25, 37-47.	2.2	40
16	Circulating Interleukin-6, Soluble CD14, and Other Inflammation Biomarker Levels Differ Between Obese and Nonobese HIV-Infected Adults on Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1019-1025.	1.1	40
17	African Mitochondrial DNA Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 1703-1707.	4.0	38
18	Machine learning selected smoking-associated DNA methylation signatures that predict HIV prognosis and mortality. <i>Clinical Epigenetics</i> , 2018, 10, 155.	4.1	37

#	ARTICLE	IF	CITATIONS
19	Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. <i>Pharmacogenomics</i> , 2009, 10, 623-637.	1.3	35
20	Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: Use of a rapid screening tool during routine clinic visits. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 109-117.	1.2	34
21	Highly Sensitive C-Reactive Protein, Body Mass Index, and Serum Lipids in HIV-Infected Persons Receiving Antiretroviral Therapy: A Longitudinal Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 480-487.	2.1	32
22	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. <i>Clinical Infectious Diseases</i> , 2021, 73, e2153-e2163.	5.8	32
23	Postpartum Discontinuation of Antiretroviral Therapy and Risk of Maternal AIDS-Defining Events, Non-AIDS-Defining Events, and Mortality Among a Cohort of HIV-Infected Women in the United States. <i>AIDS Patient Care and STDs</i> , 2010, 24, 279-286.	2.5	31
24	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2016, 213, 1065-1073.	4.0	31
25	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. <i>Journal of Neuroinflammation</i> , 2017, 14, 72.	7.2	30
26	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e103123.	2.5	29
27	Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 163-175.	1.8	29
28	Daily Marijuana Use is Associated with Missed Clinic Appointments Among HIV-Infected Persons Engaged in HIV Care. <i>AIDS and Behavior</i> , 2017, 21, 1996-2004.	2.7	28
29	Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. <i>Clinical Infectious Diseases</i> , 2015, 61, 1476-1484.	5.8	27
30	Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 413-426.	1.7	26
31	Clinical Factors Associated with Plasma F ₂ -Isoprostane Levels in HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2009, 10, 181-192.	2.0	24
32	Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. <i>Journal of NeuroVirology</i> , 2012, 18, 511-520.	2.1	24
33	Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 78-86.	4.7	22
34	HIV and Mitochondria: More Than Just Drug Toxicity. <i>Journal of Infectious Diseases</i> , 2012, 205, 1769-1771.	4.0	22
35	Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update. <i>Current HIV/AIDS Reports</i> , 2018, 15, 223-232.	3.1	22
36	Pharmacogenomics of antimicrobial agents. <i>Pharmacogenomics</i> , 2014, 15, 1903-1930.	1.3	21

#	ARTICLE	IF	CITATIONS
37	Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults. <i>Fluids and Barriers of the CNS</i> , 2017, 14, 11.	5.0	21
38	The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy. <i>AIDS Reviews</i> , 2013, 15, 213-20.	1.0	21
39	Race, Kidney Disease Progression, and Mortality Risk in HIV-Infected Persons. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2269-2275.	4.5	20
40	Implications of T-Cell P-Glycoprotein Activity During HIV-1 Infection and Its Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 119-126.	2.1	19
41	Mitochondrial Genomics and CD4 T-Cell Count Recovery After Antiretroviral Therapy Initiation in AIDS Clinical Trials Group Study 384. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 363-370.	2.1	19
42	The relationship between injection and noninjection drug use and HIV disease progression. <i>Journal of Substance Abuse Treatment</i> , 2011, 41, 14-20.	2.8	17
43	Mitochondrial Genomics and Antiretroviral Therapy-Associated Metabolic Complications in HIV-Infected Black South Africans: A Pilot Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1031-1039.	1.1	17
44	Oxidant Stress and Peripheral Neuropathy During Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 450-454.	2.1	16
45	Peripheral Blood Mitochondrial DNA Copy Number Obtained From Genome-Wide Genotype Data Is Associated With Neurocognitive Impairment in Persons With Chronic HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e95-e102.	2.1	16
46	Toward a Pharmacogenetic Understanding of Nucleotide and Nucleoside Analogue Toxicity. <i>Journal of Infectious Diseases</i> , 2006, 194, 1471-1474.	4.0	14
47	Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy. <i>Epidemiology</i> , 2010, 21, 698-705.	2.7	14
48	Mitochondrial DNA Haplogroups and Delirium During Sepsis. <i>Critical Care Medicine</i> , 2019, 47, 1065-1071.	0.9	14
49	Higher Plasma Myeloperoxidase Levels Are Not Associated with an Increased Risk for Cardiovascular Events in HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2008, 9, 207-211.	2.0	13
50	Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. <i>BMC Infectious Diseases</i> , 2014, 14, 508.	2.9	13
51	Higher Serum Iron Is Associated With Increased Oxidant Stress in HIV-Infected Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 367-373.	2.1	12
52	Human Genomic Association Studies: A Primer for the Infectious Diseases Specialist. <i>Journal of Infectious Diseases</i> , 2007, 195, 1737-1744.	4.0	11
53	Mitochondrial DNA Variation and Changes in Adiponectin and Endothelial Function in HIV-Infected Adults After Antiretroviral Therapy Initiation. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1293-1299.	1.1	11
54	Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy. <i>Aids</i> , 2021, 35, 439-445.	2.2	11

#	ARTICLE	IF	CITATIONS
55	Serum Leptin Level Mediates the Association of Body Composition and Serum C-Reactive Protein in HIV-Infected Persons on Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 552-557.	1.1	10
56	Hepatitis C Management and the Infectious Diseases Physician: A Survey of Current and Anticipated Practice Patterns: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 792-794.	5.8	10
57	Mood Disorders and Increased Risk of Noncommunicable Disease in Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 397-404.	2.1	10
58	Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 729-737.	5.0	9
59	The Role of Mitochondrial DNA Variation in Age-Related Decline in Gait Speed Among Older Men Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2018, 67, 778-784.	5.8	9
60	New Faces of HIV Infection: Age, Race, and Timing of Entry into HIV Care in the Southeastern United States. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 347-352.	1.5	8
61	Subjective memory complaints are associated with poorer cognitive performance in adults with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 654-659.	1.2	8
62	Self-reported Cannabis Use and Changes in Body Mass Index, CD4 T-Cell Counts, and HIV-1 RNA Suppression in Treated Persons with HIV. <i>AIDS and Behavior</i> , 2020, 24, 1275-1280.	2.7	8
63	Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 277-82.	2.1	8
64	Agreement of Decision Analyses and Subsequent Clinical Studies in Infectious Diseases. <i>American Journal of Medicine</i> , 2007, 120, 461.e1-461.e9.	1.5	7
65	Sociodemographic Factors Predict Early Discontinuation of HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors. <i>Journal of the National Medical Association</i> , 2008, 100, 1417-1424.	0.8	7
66	Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial. <i>Mediators of Inflammation</i> , 2014, 2014, 1-10.	3.0	7
67	Lower Concentrations of Circulating Medium and Long-Chain Acylcarnitines Characterize Insulin Resistance in Persons with HIV. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 536-543.	1.1	7
68	Brief Report: Circulating Markers of Immunologic Activity Reflect Adiposity in Persons With HIV on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 135-140.	2.1	7
69	Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 358-366.	2.1	7
70	T Cell Activation Markers and African Mitochondrial DNA Haplogroups among Non-Hispanic Black Participants in AIDS Clinical Trials Group Study 384. <i>PLoS ONE</i> , 2012, 7, e43803.	2.5	7
71	European Mitochondrial DNA Haplogroups are Associated with Cerebrospinal Fluid Biomarkers of Inflammation in HIV Infection. <i>Pathogens and Immunity</i> , 2016, 1, 330.	3.1	7
72	An association between adiposity and serum levels of macrophage inflammatory protein-1 alpha and soluble CD14 in HIV-infected adults: results from a cross-sectional study. <i>Antiviral Therapy</i> , 2013, 18, 729-733.	1.0	6

#	ARTICLE	IF	CITATIONS
73	Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy. <i>Aids</i> , 2014, 28, 1625-1633.	2.2	6
74	Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv059.	0.9	6
75	Mitochondrial Haplogroups as a Risk Factor for Herpes Zoster. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw184.	0.9	6
76	Mitochondrial DNA Haplogroups and Frailty in Adults Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 214-219.	1.1	6
77	Nucleic acid oxidation is associated with biomarkers of neurodegeneration in CSF in people with HIV. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	6
78	Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy. <i>Antiviral Therapy</i> , 2011, 17, 485-493.	1.0	5
79	Iron-regulatory genes are associated with Neuroimaging measures in HIV infection. <i>Brain Imaging and Behavior</i> , 2020, 14, 2037-2049.	2.1	5
80	Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 193-199.	1.1	5
81	African Mitochondrial DNA Haplogroup L2 Is Associated With Slower Decline of β -cell Function and Lower Incidence of Diabetes Mellitus in Non-Hispanic, Black Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e218-e225.	5.8	5
82	Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1081-1088.	1.9	4
83	Anthropometric Differences between HIV-Infected Individuals Prior to Antiretroviral Treatment and the General Population from 1998â€“2007: The AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) Cohort and NHANES. <i>PLoS ONE</i> , 2013, 8, e65306.	2.5	4
84	An Innovative Approach to Addressing the HIV Care Continuum: Implementation of a Clinical Pharmacy Resident in a Veterans Affairs HIV Specialty Clinic. <i>Journal of Pharmacy Practice</i> , 2018, 31, 422-428.	1.0	4
85	Hemochromatosis (<i>HFE</i>) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 942-949.	1.1	4
86	Phosphodiesterase Type-5 Inhibitors and the Reemerging HIV Epidemic. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1426.	7.4	3
87	Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy. <i>PLoS ONE</i> , 2020, 15, e0239758.	2.5	3
88	Chronic kidney disease at presentation is not an independent risk factor for AIDS-defining events or death in HIV-infected persons. <i>Clinical Nephrology</i> , 2013, 79, 93-100.	0.7	3
89	QSART for diagnosis of statin-associated polyneuropathy. <i>Muscle and Nerve</i> , 2011, 43, 295-296.	2.2	2
90	Mitochondrial DNA haplogroups and domain-specific neurocognitive performance in adults with HIV. <i>Journal of NeuroVirology</i> , 2021, 27, 557-567.	2.1	2

#	ARTICLE	IF	CITATIONS
91	Higher CSF Ferritin Heavy-Chain (Fth1) and Transferrin Predict Better Neurocognitive Performance in People with HIV. <i>Molecular Neurobiology</i> , 2021, 58, 4842-4855.	4.0	2
92	Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial. <i>PLoS ONE</i> , 2017, 12, e0170515.	2.5	2
93	Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens. <i>Open Forum Infectious Diseases</i> , 2017, 4, S433-S433.	0.9	1
94	Precision HIV care: responding to old questions and meeting new challenges. <i>Pharmacogenomics</i> , 2018, 19, 1299-1302.	1.3	1
95	Mitochondria and Human Immunodeficiency Virus: A Troubled Relationship Enters Its Fourth Decade. <i>Clinical Infectious Diseases</i> , 2020, 73, e474-e476.	5.8	1
96	A Haptoglobin Exon Copy Number Variant Associates With HIV-Associated Neurocognitive Impairment in European and African-Descent Populations. <i>Frontiers in Genetics</i> , 2021, 12, 756685.	2.3	1
97	Nucleoside and nucleotide analogue reverse transcriptase inhibitor toxicity: how much longer must we wield the sword?. <i>Future HIV Therapy</i> , 2007, 1, 61-72.	0.4	0
98	1135High rates of self-reported alcohol use in HIV/HCV co-infected and HIV mono-infected patients in a Southeastern U.S. Cohort. <i>Open Forum Infectious Diseases</i> , 2014, 1, S337-S337.	0.9	0
99	1540New Faces of HIV Infection: Differences between Younger and Older Persons Presenting for HIV Care in Nashville, Tennessee. <i>Open Forum Infectious Diseases</i> , 2014, 1, S409-S410.	0.9	0
100	1605Active Marijuana Use Was Not Associated with Changes in Body Mass Index or CD4 T-Cell Counts in HIV-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2014, 1, S428-S428.	0.9	0
101	Analysis of HIV/Hepatitis C Virus (HCV) Coinfection and Mortality Across Cohorts of HIV+ Patients in Middle Tennessee. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0